Meeting News

Top takeaways from Heart in Diabetes 2019

Endocrine Today has compiled a list of the top five news reports posted from Heart in Diabetes, held July 12-14, 2019, in Philadelphia.

Healio.com/Endocrinology readers were interested in the effects of hypoglycemia on cognitive and cardiovascular disease, metformin use in type 1 diabetes and more.

All content from the meeting is available under the Meeting News tab.

Severe hypoglycemia indicates cardiovascular, cognitive danger

Severe hypoglycemic events can present cardiovascular and cognitive risks, and hypoglycemia should signal a call to action for physicians treating the patients with diabetes.

READ

Metformin shows promise for vascular health in adolescents with type 1 diabetes

Adolescents with type 1 diabetes already show early hallmarks of cardiovascular disease, and an intervention with a commonly used type 2 diabetes therapy can improve their vascular health and reduce future CV risk.

READ

Weight loss mediates CV damage of fatty liver in diabetes

Nonalcoholic fatty liver disease is an “unrecognized epidemic” among people with type 2 diabetes.

READ

Trial data highlight need for redefined guidelines for older adults with diabetes

Older adults with type 2 diabetes can derive meaningful cardiovascular and renal benefits from newer antihyperglycemic agents, and data from several large CV outcomes trials suggest that treatment guidelines for this population should be redefined to reflect such findings.

READ

Ethnicity, age, sex influence CV risk in type 2 diabetes

The growing global burden of type 2 diabetes and cardiovascular disease disproportionately affects people living in countries experiencing large social transitions, with women and those diagnosed before age 40 years more likely to experience worse disease outcomes.

READ

Endocrine Today has compiled a list of the top five news reports posted from Heart in Diabetes, held July 12-14, 2019, in Philadelphia.

Healio.com/Endocrinology readers were interested in the effects of hypoglycemia on cognitive and cardiovascular disease, metformin use in type 1 diabetes and more.

All content from the meeting is available under the Meeting News tab.

Severe hypoglycemia indicates cardiovascular, cognitive danger

Severe hypoglycemic events can present cardiovascular and cognitive risks, and hypoglycemia should signal a call to action for physicians treating the patients with diabetes.

READ

Metformin shows promise for vascular health in adolescents with type 1 diabetes

Adolescents with type 1 diabetes already show early hallmarks of cardiovascular disease, and an intervention with a commonly used type 2 diabetes therapy can improve their vascular health and reduce future CV risk.

READ

Weight loss mediates CV damage of fatty liver in diabetes

Nonalcoholic fatty liver disease is an “unrecognized epidemic” among people with type 2 diabetes.

READ

Trial data highlight need for redefined guidelines for older adults with diabetes

Older adults with type 2 diabetes can derive meaningful cardiovascular and renal benefits from newer antihyperglycemic agents, and data from several large CV outcomes trials suggest that treatment guidelines for this population should be redefined to reflect such findings.

READ

Ethnicity, age, sex influence CV risk in type 2 diabetes

The growing global burden of type 2 diabetes and cardiovascular disease disproportionately affects people living in countries experiencing large social transitions, with women and those diagnosed before age 40 years more likely to experience worse disease outcomes.

READ

    See more from Heart in Diabetes